FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002134787> ?p ?o ?g. }

• W2002134787 endingPage "e84" @default.
• W2002134787 startingPage "e73" @default.
• W2002134787 abstract "OBJECTIVE. With this study we assessed the efficacy and safety of an extended-release formulation of guanfacine compared with placebo for the treatment of children and adolescents with attention-deficit/hyperactivity disorder. METHODS. In this multicenter, double-blind, placebo-controlled, fixed-dosage escalation study, patients aged 6 to 17 years were randomly assigned to 1 of 3 treatment groups of guanfacine extended release (2, 3, or 4 mg/day) or placebo for 8 weeks. The primary outcome measurement was the Attention-Deficit/Hyperactivity Disorder Rating Scale IV total score. Secondary measurements included Clinical Global Impression of Improvement, Parent's Global Assessment, Conners' Parent Rating Scale–Revised: Short Form, and Conners' Teacher Rating Scale–Revised: Short Form. RESULTS. A total of 345 patients were randomly assigned to placebo (n = 86) or guanfacine extended release 2 mg (n = 87), 3 mg (n = 86), or 4 mg (n = 86) treatment groups. Least-squares mean changes from baseline to the end point in Attention-Deficit/Hyperactivity Disorder Rating Scale IV total scores were significant in all groups of children taking guanfacine extended release: −16.18 in the 2-mg group, −16.43 in the 3-mg group, and −18.87 in the 4-mg group, compared with −8.48 in the placebo group. All groups of children taking guanfacine extended release showed significant improvement on hyperactivity/impulsivity and inattentiveness subscales of the Attention-Deficit/Hyperactivity Disorder Rating Scale IV, Clinical Global Impression of Improvement, Parent's Global Assessment, Conners' Parent Rating Scale–Revised: Short Form, and Conners' Teacher Rating Scale–Revised: Short Form assessments compared with placebo. The most commonly reported treatment-emergent adverse events were headache, somnolence, fatigue, upper abdominal pain, and sedation. Small to modest changes in blood pressure, pulse rate, and electrocardiogram parameters were observed but were not clinically meaningful. CONCLUSIONS. Guanfacine extended release met the primary and secondary efficacy end points. It was well tolerated and effective compared with placebo." @default.
• W2002134787 created "2016-06-24" @default.
• W2002134787 creator A5003395204 @default.
• W2002134787 creator A5019464255 @default.
• W2002134787 creator A5024768165 @default.
• W2002134787 creator A5027354439 @default.
• W2002134787 creator A5033482204 @default.
• W2002134787 creator A5068382742 @default.
• W2002134787 creator A5072537038 @default.
• W2002134787 date "2008-01-01" @default.
• W2002134787 modified "2023-09-29" @default.
• W2002134787 title "A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder" @default.
• W2002134787 cites W1501686051 @default.
• W2002134787 cites W1973930439 @default.
• W2002134787 cites W1978755811 @default.
• W2002134787 cites W1982166376 @default.
• W2002134787 cites W2002691701 @default.
• W2002134787 cites W2003848021 @default.
• W2002134787 cites W2015106736 @default.
• W2002134787 cites W2016483680 @default.
• W2002134787 cites W2018897037 @default.
• W2002134787 cites W2029643412 @default.
• W2002134787 cites W2039755273 @default.
• W2002134787 cites W2042702082 @default.
• W2002134787 cites W2053548987 @default.
• W2002134787 cites W2053758131 @default.
• W2002134787 cites W2067292897 @default.
• W2002134787 cites W2067355648 @default.
• W2002134787 cites W2081653247 @default.
• W2002134787 cites W2083338868 @default.
• W2002134787 cites W2088839547 @default.
• W2002134787 cites W2109089666 @default.
• W2002134787 cites W2109935740 @default.
• W2002134787 cites W2112484680 @default.
• W2002134787 cites W2119599154 @default.
• W2002134787 cites W2122518346 @default.
• W2002134787 cites W2123980944 @default.
• W2002134787 cites W2147123664 @default.
• W2002134787 cites W2158377281 @default.
• W2002134787 cites W2164549762 @default.
• W2002134787 cites W2601578636 @default.
• W2002134787 cites W3139845868 @default.
• W2002134787 cites W4255249964 @default.
• W2002134787 doi "https://doi.org/10.1542/peds.2006-3695" @default.
• W2002134787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18166547" @default.
• W2002134787 hasPublicationYear "2008" @default.
• W2002134787 type Work @default.
• W2002134787 sameAs 2002134787 @default.
• W2002134787 citedByCount "269" @default.
• W2002134787 countsByYear W20021347872012 @default.
• W2002134787 countsByYear W20021347872013 @default.
• W2002134787 countsByYear W20021347872014 @default.
• W2002134787 countsByYear W20021347872015 @default.
• W2002134787 countsByYear W20021347872016 @default.
• W2002134787 countsByYear W20021347872017 @default.
• W2002134787 countsByYear W20021347872018 @default.
• W2002134787 countsByYear W20021347872019 @default.
• W2002134787 countsByYear W20021347872020 @default.
• W2002134787 countsByYear W20021347872021 @default.
• W2002134787 countsByYear W20021347872022 @default.
• W2002134787 countsByYear W20021347872023 @default.
• W2002134787 crossrefType "journal-article" @default.
• W2002134787 hasAuthorship W2002134787A5003395204 @default.
• W2002134787 hasAuthorship W2002134787A5019464255 @default.
• W2002134787 hasAuthorship W2002134787A5024768165 @default.
• W2002134787 hasAuthorship W2002134787A5027354439 @default.
• W2002134787 hasAuthorship W2002134787A5033482204 @default.
• W2002134787 hasAuthorship W2002134787A5068382742 @default.
• W2002134787 hasAuthorship W2002134787A5072537038 @default.
• W2002134787 hasConcept C118552586 @default.
• W2002134787 hasConcept C126322002 @default.
• W2002134787 hasConcept C138496976 @default.
• W2002134787 hasConcept C142724271 @default.
• W2002134787 hasConcept C15744967 @default.
• W2002134787 hasConcept C168563851 @default.
• W2002134787 hasConcept C187212893 @default.
• W2002134787 hasConcept C202061045 @default.
• W2002134787 hasConcept C204787440 @default.
• W2002134787 hasConcept C27081682 @default.
• W2002134787 hasConcept C2776000289 @default.
• W2002134787 hasConcept C2778399450 @default.
• W2002134787 hasConcept C2780319597 @default.
• W2002134787 hasConcept C2780783007 @default.
• W2002134787 hasConcept C2780815205 @default.
• W2002134787 hasConcept C2991744798 @default.
• W2002134787 hasConcept C42219234 @default.
• W2002134787 hasConcept C71924100 @default.
• W2002134787 hasConcept C83849319 @default.
• W2002134787 hasConceptScore W2002134787C118552586 @default.
• W2002134787 hasConceptScore W2002134787C126322002 @default.
• W2002134787 hasConceptScore W2002134787C138496976 @default.
• W2002134787 hasConceptScore W2002134787C142724271 @default.
• W2002134787 hasConceptScore W2002134787C15744967 @default.
• W2002134787 hasConceptScore W2002134787C168563851 @default.
• W2002134787 hasConceptScore W2002134787C187212893 @default.
• W2002134787 hasConceptScore W2002134787C202061045 @default.
• W2002134787 hasConceptScore W2002134787C204787440 @default.
• W2002134787 hasConceptScore W2002134787C27081682 @default.

• next